Olpaza 150mg Tablet Exporter from India | Bulk Olaparib Supply to Washington, London, Bangkok, Canberra, Singapore, & Kingston | Ernest Impex

Olpaza 150mg Tablet: Advanced Targeted PARP Inhibitor for BRCA-Mutated and Advanced Oncology Care

Extensive Product Profile: In-Depth Insights on Olpaza 150mg Tablets

Olpaza 150mg Tablet, manufactured under strict global compliance systems within India by Intas Pharmaceuticals Ltd., is a breakthrough oral targeted antineoplastic therapy. Each film-coated tablet contains precisely Olaparib ($150text{ mg}$) as its active pharmaceutical ingredient. Olaparib is a first-in-class, highly advanced PARP (Poly ADP-ribose Polymerase) inhibitor designed to exploit specific genetic vulnerabilities within tumor cells, providing a targeted mechanism that spares many healthy tissues while eliminating cancerous growths.

1. Clinical Indications & Target Therapeutic Applications

Advanced Ovarian Cancer: Utilized as a vital maintenance monotherapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line or recurrent platinum-based chemotherapy.

gBRCAm HER2-Negative Breast Cancer: Indicated for patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

2. Comprehensive Mechanism of Action (MOA)

PARP Enzyme Inhibition: Olpaza binds directly to and inhibits the PARP enzymes (PARP-1, PARP-2, and PARP-3). PARP proteins are crucial for repairing single-strand DNA breaks via the Base Excision Repair pathway.

PARP Trapping: Beyond simple inhibition, the presence of Olaparib traps the PARP enzymes on the damaged DNA strands, stabilizing the complex. When the cell attempts to replicate, these trapped complexes cause the single-strand breaks to collapse into highly lethal double-strand DNA breaks.

3. Storage, Stability, and Handling Protocols

Environmental Matrix: Store Olpaza 150mg Tablets in their original moisture-sealed manufacturer blister packaging or bottle at a controlled room temperature between 10°C to 30°C (50°F to 86°F). Protect the inventory from high ambient steam, humidity, heat, and direct light exposure.

Administration Matrix: The standard therapeutic dosage is typically 300 mg (two 150 mg tablets) taken orally twice daily (morning and evening) with or without food. Tablets must be swallowed completely whole with a glass of water. Do not crush, chew, open, split, or dissolve the tablets, as this alters the designated absorption rates and drug delivery performance.

Potential Side Effects of Olpaza 150mg

Hematological Toxicity (Myelosuppression): Frequently causes notable decreases in blood cell counts, resulting in severe anemia (low red blood cells), neutropenia (low white blood cells making patients vulnerable to infections), and thrombocytopenia (low platelets increasing bruising risks). Regular Complete Blood Counts (CBC) are required monthly.

Gastrointestinal Distress: Very common side effects include persistent nausea, vomiting, diarrhea, constipation, dyspepsia (indigestion), a notable loss of appetite, and altered taste sensations (dysgeusia).

Export Documentation & Global Trade Compliance

Certificate of Analysis (COA): Providing verifiable batch testing confirming the precise $150text{ mg}$ Olaparib strength, active dissolution profiles, and chemical purity indices.

Certificate of Origin (COO): Authenticating true manufacturing provenance within registered Indian oncology production lines.

Customs-Compliant Manifesting: Precision shipping manifests, clean packing lists, and commercial invoicing marked with correct global harmonized system (HS) codes for seamless clearance.

PRESCRIPTION MEDICINE IS YES

Disclaimer: This structural product review is prepared strictly for international business-to-business (B2B) trade procurement, wholesale distribution networks, and digital optimization indexing. Olpaza 150mg Tablet (Olaparib) is a high-potency, restricted prescription oncology medication. It must be prescribed and managed exclusively by qualified medical professionals in a specialized clinical setting. It is highly unsafe for use during pregnancy or breastfeeding because this can cause harmful effects and severe developmental damage to the unborn baby

📞 Contact Ernest Impex — Pharmaceutical Exporter from India

[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]

🌐 Websites:

www.ernestimpex.com

www.ernestvision.com

www.oncologymedicinesupplier.com

www.ernestpharmaceuticals.com

📧 Email: exports@ernestpharmaceuticals.com

📦 Business Type: Exporter | Bulk Supplier | Distributor

📲 WhatsApp: +91 93599 02383

📲 WhatsApp Link: https://wa.me/919359902383